M García1, M A Aranburu2, I Palacios-Zabalza3, U Lertxundi4, C Aguirre1,5. 1. Basque Country Pharmacovigilance Unit, Galdakao-Usansolo Hospital, Galdakao, Spain. 2. Mutriku Primary Health Care, Mutriku, Spain. 3. Pharmacy Service, Galdakao-Usansolo Hospital, Galdakao, Spain. 4. Pharmacy Service, Araba's Mental Health Network, Vitoria-Gasteiz, Spain. 5. Department of Pharmacology, Faculty of Medicine, University of Basque Country, Leioa, Spain.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. CASE SUMMARY: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. WHAT IS NEW AND CONCLUSION: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.
WHAT IS KNOWN AND OBJECTIVE: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. CASE SUMMARY: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. WHAT IS NEW AND CONCLUSION: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.